Form 4: MacroGenics COO Exercises Options and Sells Shares Under 10b5-1 Plan

Eric Blasius Risser, Chief Operating Officer of MacroGenics, Inc., exercised stock options and sold shares of common stock under a pre-arranged trading plan.

Summary

• On March 4, 2024, Eric Blasius Risser, the Chief Operating Officer of MacroGenics, Inc., exercised options to purchase 15,000 shares of common stock at a price of $10.15 per share.
• Simultaneously, Risser sold 15,000 shares at $20 and 26,159 shares at prices ranging from $19.50 to $19.78.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 21, 2022.
• Following these transactions, Risser directly owns 38,900 shares of MacroGenics common stock and holds options for 155,000 shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing insider transactions. It doesn't convey any explicit positive or negative sentiment about the company's performance or prospects. The transactions appear to be part of a pre-arranged plan, reducing the signal value.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of insider transactions. It's common for executives to exercise stock options and sell shares, often under pre-arranged trading plans like Rule 10b5-1, to manage personal finances. The market typically analyzes these transactions to gauge insider sentiment, but pre-planned sales are generally viewed as less informative than discretionary trades.

Comparison to Industry Standards

• Rule 10b5-1 trading plans are a common practice among corporate executives to avoid accusations of insider trading.
• The details of the plan are not disclosed, so it is not possible to compare the plan to industry standards.
• The sale price of $19.50 to $20 is within the normal range for stock sales by executives.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership.
• The impact on employees, customers, suppliers, and creditors is likely to be negligible.

Key Dates